Neil Iyengar, MD, Oncology, New York, NY, Memorial Sloan-Kettering Cancer Center

NeilMukundIyengarMD

Oncology New York, NY

Breast Cancer, Hematologic Oncology

Physician

Dr. Iyengar is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Iyengar's full profile

Already have an account?

  • Office

    300 E 66th Street Office 823
    Evelyn H. Lauder Breast and Imaging Center, Memorial Sloan Kettering
    New York, NY 10065
    Phone(646) 888-4711
    Fax(646) 888-4917
  • Is this information wrong?

Summary

  • Dr. Neil Iyengar is a medical oncologist and clinical-translational researcher at Memorial Sloan Kettering Cancer Center (MSKCC) where he specializes in the care of patients with breast cancer. He also holds joint research appointments at the Rockefeller University Center for Clinical and Translational Science and Weill Cornell Medical College (WCMC) in New York. He received his undergraduate and medical degrees from the University of Illinois College of Medicine accelerated program in Chicago. He then went on to complete residency training in Internal Medicine at the University of Chicago followed by fellowship in medical oncology and hematology at MSKCC. Dr. Iyengar studies the role of obesity and inflammation in the development and progression of breast and several other cancers. He is Co-Leader of the MSKCC-WCMC Obesity & Cancer Working Group, a multi-institutional translational research team composed of laboratory scientists and clinicians. This group was the first to report obesity-related inflammation in the breast as a putative mechanism of carcinogenesis. Dr. Iyengar has been recognized for his work by several organizations including the Conquer Cancer Foundation of the American Society of Clinical Oncology, the Breast Cancer Research Foundation, National Comprehensive Cancer Network, the American Association for Cancer Research, and others. He has been invited to present his work at international meetings and he has published several peer reviewed articles. Dr. Iyengar is now expanding his work to develop specific interventions, including diets, exercise programs, and medications, that target adipose tissue inflammation in order to protect patients from its harmful cancer-promoting effects.

Education & Training

  • Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer CenterFELLOWSHIP
  • University of Chicago
    University of ChicagoRESIDENCY
  • University of Illinois College of Medicine
    University of Illinois College of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2020 - 2021
  • NY State Medical License
    NY State Medical License 2011 - 2022
  • IL State Medical License
    IL State Medical License 2008 - 2011
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Extended Mutational Profiling By MSK-IMPACTTM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor MalignancyClinically Relevant Abstract
    Neil Iyengar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Improving risk assessment of obesity-associated breast cancer. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Triplet Active in Anti-HER2-Exposed Metastatic Breast Ca
    Triplet Active in Anti-HER2-Exposed Metastatic Breast CaNovember 29, 2019
  • Another Weight-Loss Surgery Benefit: Lower Breast Cancer Risk
    Another Weight-Loss Surgery Benefit: Lower Breast Cancer Risk
  • Efficacy and Safety of Gemcitabine with Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial
    Efficacy and Safety of Gemcitabine with Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical TrialNovember 01, 2019
  • Join now to see all

Hospital Affiliations